The manufacturers of Tradjenta are likely to face lawsuits over the drug's possible link to pancreatitis and pancreatic cancer.
Approved in May 2011, Tradjenta joined a growing market of popular type 2 diabetes treatments. Unfortunately, concerns about dangerous side effects have plagued a number of type 2 diabetes drugs that have entered the pharmaceutical market in recent years. New research suggests that Tradjenta may also carry undisclosed risks. According to research published in February 2013, the drug may be linked to an increased risk of pancreatitis and pre-cancerous changes in the pancreas.
Tradjenta, also known by its generic name linagliptin, is the product of collaboration between U.S. pharmaceutical giant Eli Lilly & Co. and German-based drug manufacturer Boehringer Ingelheim. It is taken orally to control blood sugar levels and has been approved as an "add-on" therapy to insulin. It belongs to the DPP-4 inhibitor class of drugs. It allows incretin to remain in the body longer, triggering the release of insulin after eating.
Two related diabetes drugs -- Januvia and Byetta – also affect the levels of incretin and insulin in the body. People who have taken those drugs have developed pancreatic diseases. Many of them have filed lawsuits in federal and state courts alleging that Januvia and Byetta manufacturers and marketers failed to warn about increased risk of developing pancreatic cancer and other pancreatic diseases. Tradjenta may be on the similar path wrought with preventable injuries and leading to litigation.
Status of Tradjenta Lawsuits
In May 2013, the Food and Drug Administration (FDA) alerted the public to the troubling research linking certain drugs, including Tradjenta, to pancreatitis and pancreatic duct metaplasia in type 2 diabetes patients. The FDA has asked the medical researchers to provide more information about their findings so that it can further investigate the risks.
Meanwhile, Tradjenta's makers continue to market the drug, and it remains available by prescription. The FDA doesn't necessarily take a drug off the market because of severe health risks. Drugmakers usually don't recall dangerous drugs or update warning labels until many people have already been injured.
However, as is often the case, attention from independent medical researchers and injured consumers who file lawsuits can bring attention to previously undisclosed dangers and perhaps encourage a faster response. For this reason, lawsuits alleging Tradjenta injuries are expected to be filed in the coming months.
How We Can Help
As more details about the possible connection between Tradjenta and pancreatic cancer emerge, Eli Lilly and Boehringer Ingelheim will face scrutiny of how they manufactured, tested and marketed the drug, as well as how they disclosed its risks.
Tradjenta’s label already warns about pancreatitis risks. But the recent research raises concerns about even more severe health risks. Consumers and their physicians are entitled to information about any adverse effects before the decision is made to use a treatment. This is particularly important when the potential risks are more severe than the underlying condition that the drug claims to treat. When drugmakers fail to provide this information, they may be held legally liable for resulting injuries.
Attorneys who are experienced in handling prescription drug lawsuits can help because they understand the legal duties imposed on drugmakers. They can evaluate the drugmakers' marketing efforts and warnings to identify possible negligence. They can also review the facts of a particular case to determine if someone is eligible to file a legal claim for compensation.
In addition, these attorneys can help in the event of a recall. Drugmakers that voluntarily recall products often use the recall as an opportunity to get an injured consumer to waive the right to file a lawsuit. Consulting an attorney is a good idea because he or she can help consumers avoid doing anything that could hurt their chances to receive a larger amount of compensation for their injuries.
Why Should You File a Tradjenta Lawsuit?
Many drugs with severe side effects are never actually recalled. And even if a harmful drug is recalled, consumers often find that the compensation offered by drugmakers during the recall is not enough to cover medical expenses and other losses caused by their injuries. People file prescription drug lawsuits to ensure that they have enough resources to provide for their households and get needed medical treatment while they are injured.
People who are injured by Tradjenta may be able to receive compensation for the following:
- Medical expenses related to the injury (including the costs of doctor visits, hospitalization, home health care and medication).
- Lost wages from inability to work.
- Pain and emotional suffering.
- Loss of consortium (e.g., disruption of a relationship with a spouse and family).
- Punitive damages to discourage further misconduct.